Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00174837
- Locations
- 🇳🇿
sanofi-aventis New Zealand administrative office, Macquarie Park, New Zealand
🇨🇳Sanofi-Aventis Administrative Office, Taipei, Taiwan
Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma
- Conditions
- Asthma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1145
- Registration Number
- NCT00174746
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
EXIBIT: Oxaliplatin in Biliary Tract Cancer
- Conditions
- Biliary Tract Neoplasms
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT00174564
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00174798
- Locations
- 🇺🇸
Hudson Valley Urology Center, Kingston, New York, United States
🇺🇸Hudson Valley Urology, Poughkeepsie, New York, United States
🇺🇸Rockhill Medical Plaza, Kansas City, Missouri, United States
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
- Conditions
- Asthma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 708
- Registration Number
- NCT00174720
- Locations
- 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
- Conditions
- Asthma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 456
- Registration Number
- NCT00174733
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections
- Conditions
- Otitis Media
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 639
- Registration Number
- NCT00174811
- Locations
- 🇫🇷
Sanofi- Aventis Administrative Office, Paris, France
🇺🇸Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1024
- Registration Number
- NCT00174824
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
- Conditions
- Atrial FibrillationAtrial Flutter
- Interventions
- Drug: placebo
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4628
- Registration Number
- NCT00174785
- Locations
- 🇩🇪
Sanofi-aventis Administrative Office, Berlin, Germany
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
GILT Docetaxel - Non-Small Cell Lung Cancer
- Conditions
- Lung Neoplasms
- Interventions
- Drug: docetaxel/gemcitabineDrug: Docetaxel/DDP
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 449
- Registration Number
- NCT00174629
- Locations
- 🇨🇭
Sanofi-Aventis, Genève, Switzerland